Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancers

2018 ◽  
Vol 149 ◽  
pp. 70
Author(s):  
G. Altwerger ◽  
E. Bonazzoli ◽  
S. Bellone ◽  
T. Takata ◽  
G. Menderes ◽  
...  
Keyword(s):  
Folate Receptor ◽  
Type Ii ◽  
Antibody Drug Conjugate ◽  
Folate Receptor Alpha ◽  
Receptor Alpha ◽  
Drug Conjugate ◽  
Endometrial Cancers ◽  
Antibody Drug

Safety Profile of Mirvetuximab Soravtansine, a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Patients with Recurrent Ovarian Cancer

2020 ◽  
Vol 156 (3) ◽  
pp. e15-e16
Author(s):  
Kathleen G. Essel ◽  
Lainie P. Martin ◽  
David M. O’Malley ◽  
Ursula Matulonis ◽  
Jason A. Konner ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Safety Profile ◽  
Folate Receptor ◽  
Recurrent Ovarian Cancer ◽  
Antibody Drug Conjugate ◽  
Folate Receptor Alpha ◽  
Receptor Alpha ◽  
Drug Conjugate ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document